A Phase I Study of the Optimized Cryptic Peptide TERT<sub>572Y</sub> in Patients with Advanced Malignancies - Concepedia

Concepedia

Publication | Closed Access

A Phase I Study of the Optimized Cryptic Peptide TERT<sub>572Y</sub> in Patients with Advanced Malignancies

55

Citations

28

References

2006

Year

Dimitriοs Mavroudis, Irena Bolonakis, Sébastien Cornet, G. Myllaki, Peggy Kanellou, Athanasios Galanis, Irini Nikoloudi, M. Spyropoulou, Jeanne Menez, Isabelle Miconnet,

Abstract

TERT(572Y) peptide vaccine is well tolerated and effective in eliciting specific TERT(572Y) CD8+ lymphocytes in pretreated cancer patients, demonstrating that cryptic peptides could be used in cancer immunotherapy.

References

	Year	Citations

Page 1